文献速递肺结节与肺癌

日本HER2异常肺癌临床特征与结局的前瞻性队列研究(HER2-CS STUDY)

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
PubMed 文献 · Chest · 2019-05-06

该前瞻性队列研究纳入病理确诊的IIIB/IV期或复发NSCLC且ECOG PS 0-2患者,采用IHC、FISH和直接测序筛查HER2异常。1126例肿瘤中IHC3+和IHC2+/FISH+各占3.0%,724例EGFR野生型中HER2突变占2.9%。HER2异常患者预后显著差于EGFR/ALK阳性患者,可能因靶向治疗比例低(26%)且客观缓解率低(过表达0%、突变14%)。

要点

  • HER2 IHC3+和IHC2+/FISH+各占筛查NSCLC的3.0%,HER2突变占EGFR野生型的2.9%。
  • HER2过表达与突变互斥;突变多见于女性,过表达多见于男性和吸烟者。
  • HER2异常肺癌预后差于EGFR/ALK阳性,靶向治疗比例低且缓解率低。

核心结论

  • 首次全面描述HER2阳性晚期肺癌的频率和临床人口学特征,为未来药物开发提供关键历史数据。
  • HER2异常肺癌患者预后显著差于EGFR阳性和ALK阳性患者。

研究设计与样本

  • 前瞻性队列研究,纳入病理确诊的IIIB/IV期或复发NSCLC且ECOG PS 0-2的患者。
  • 采用IHC和FISH筛查HER2过表达,直接基因测序鉴定HER2突变。
  • 共筛查1126例肿瘤,其中724例为EGFR野生型。

主要发现

  • 1126例肿瘤中34例(3.0%)为IHC3+,34例(3.0%)为IHC2+/FISH+。
  • 724例EGFR野生型肿瘤中21例(2.9%)为HER2突变,包括A775-G776insYVMA(n=15)。
  • IHC3+肿瘤与HER2突变肿瘤完全互斥。
  • 女性患者HER2突变肿瘤更常见,IHC3+和IHC2+/FISH+肿瘤在男性和吸烟者中更常检出。
  • HER2异常患者接受HER2靶向治疗比例低(n=15,26%),HER2过表达和突变患者缓解率分别为0%和14%。

关键数值与推荐

  • HER2阳性定义为IHC3+、IHC2+/FISH+或外显子20插入突变。
  • IHC3+占3.0%(34/1126),IHC2+/FISH+占3.0%(34/1126),HER2突变占EGFR野生型的2.9%(21/724)。

临床怎么用

  • 对晚期NSCLC应进行HER2 IHC、FISH和突变检测以识别HER2异常亚群。
  • HER2异常患者预后较差,需开发更有效的HER2靶向治疗策略。
  • 未来治疗策略应按HER2异常类型(过表达 vs 突变)分层制定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human epidermal growth factor 2 (HER2) is a potential driver oncogene. Although HER2-targeted precision therapy has been tested in non-small cell lung cancer (NSCLC), the demographic characteristics of HER2-positive NSCLC have not been systematically defined. METHODS: Patients with pathologically confirmed stage IIIB/IV or recurrent NSCLC, Eastern Cooperative Oncology Group performance status 0 to 2, were prospectively registered. HER2 immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assays were performed to screen patients. HER2 mutations were identified by using direct gene sequencing. The aim of this study was to clarify the frequency, characteristics, and outcome of HER2-positive NSCLC. HER2 was defined as positive if the tumor harbored IHC3+, IHC2+/FISH+, or exon 20 insertion mutations. RESULTS: Of the 1,126 tumors screened, 34 (3.0%) were IHC3+, and 34 (3.0%) were IHC2+/FISH+. Among the 724 epidermal growth factor receptor wild-type tumors, 21 (2.9%) were HER2-mutant tumors, including A775-G776insYVMA (n = 15). Interestingly, the IHC3+ tumors and mutant tumors were entirely exclusive. Female patients had HER2-mutant tumors more frequently, whereas both IHC3+ and IHC2+/FISH+ tumors were detected more often in male subjects and smokers. Patients with an HER2-aberrant tumor had a significantly worse prognosis than those with epidermal growth factor receptor-positive and anaplastic lymphoma kinase-positive tumors, possibly due to the low proportion that received HER2-targeted therapies (n = 15 [26%]) and low response rates of 0% and 14% in patients with HER2-overexpressing and HER2-mutant tumors, respectively. CONCLUSIONS: This prospective large-scale cohort study is the first to show comprehensively the frequency and clinical demographic characteristics of those with HER2-positive advanced lung tumors in detail, providing critical historical data for future drug development against HER2-positive NSCLC. Future treatment strategies would be developed stratified according to the types of HER2 aberrations. TRIAL REGISTRY: UMIN Registration No. 000017003; URL: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019691.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Ninomiya K, Hata T, Yoshioka H, et al. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY). Chest. 2019. PMID: 31072612. doi:10.1016/j.chest.2019.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。